PITTSBURGH: Mylan CEO plans to defend EpiPen price

PITTSBURGH — The Senate Banking Committee had its turn with Wells Fargo CEO John Stumpf on Tuesday. Today, the spotlight shifts to Mylan CEO Heather Bresch, who goes before the House Oversight and Government Reform Committee to testify about pricing for her company’s EpiPen, the emergency allergy shot that has seen its price increase more than 500 percent since 2007. In testimony released last night, Bresch said, “Price and access exist in a balance, and we believe we have struck that balance,”…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news